Targeted MS imaging:

quick, direct and detailed molecular spatial information

Mass spectrometry imaging (MSI) is valuable for understanding:



especially at therapeutic levels.






and low-level analytes can interfere with the accuracy and sensitivity of MSI,




However, some factors including the complexity of tissues, the presence of salt




incorporated the desirable features of two established technologies, leveraging the DESI XS and the Xevo™ TQ Absolute XR.

Waters' targeted MSI solution with DESI XS on the XevoTM TQ Absolute XR enables the most rapid and sensitive localization of drugs and their metabolites, providing crucial insights into bio-distribution, tissue penetration and target engagement.

To address detection challenges and advance MSI, targeted MS imaging has






spectrometers, ideally suited for untargeted discovery workflows

conjunction with time-of-flight mass

A targeted MS imaging solution with DESI XS and TQ Absolute XR offers a distinctive combination of features:




Widely adopted for drug quantitation in drug development workflows, enabling more informed decision-making throughout the R&D lifecycle



A targeted MS imaging solution

molecular visualization for complex MS imaging datasets from surfaces



Radiopharmaceuticals — drugs containing


radioactive isotopes — are used in medical

imaging and treatment, particularly for

counting dopamine neurons in

Parkinson's disease.

neurodegenerative disorders like




Enhances quantification

using the sensitivity and dynamic range of TQ MS

Quickly accesses lower

detection limits in



Reduces data size and

interpretation challenges

Meets laboratory sustainability goals with

low operational costs compared to other MS systems on the market



radiolabeling can lead to cost-effective, safer and faster drug development.

The biodistribution of new


radiopharmaceuticals must align

with that of the target protein.

Confirming this match before

Targeted MS imaging Discovery HRMS MRM TQ

requirements, by allowing:



Radiopharmaceuticals require

sensitive visualization methods for tracer dosing, which may not always be achievable with

high-resolution mass spectrometry

(HRMS) imaging.

compared to discovery HRMS imaging using MS and tandem MS. The tracer-dosed tissue could not be imaged by discovery HRMS imaging but was easily imaged by targeted MS imaging due to gains in sensitivity and specificity with this targeted approach. Targeted approaches to enhance efficiency in mass spectrometry imaging

This neuroimaging example portrays metabolite and lipid localization in a

mouse brain using targeted MRM MS imaging on DESI XS TQ Absolute XR

Efficient collection of a broader spectrum of

pharmaceutical

workflows on whole

studies, including

biological replicates

Targeted MS imaging utilizing DESI and Xevo TQ Absolute XR provides optimal,

direct and detailed spatial information while minimizing sample preparation

Data collection within

images in a reduced time frame

Learn more at Waters.com/TargetedMSI





Increased statistical

confidence in results

over a smaller

study summary